Nasal Drug Delivery on the Rise - What's Next for Pharma?
Summary: This case study highlights how Science 37 and Catalent successfully navigated the challenges of a Phase 3 rare disease neurology study for narcolepsy. By utilizing a Direct-to-Patient site model supported by Catalent’s specialized logistics, the partnership overcame significant geographic and condition-specific barriers, enabling efficient participant enrollment and secure, timely delivery of investigational therapies.